Teva Pharmaceutical Industries (TEVA) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $49.67B | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | IL | CEO | Richard D. Francis |
| IPO Date | 1982-02-16 | CAGR | 14.01% |
| Employees | 32,008 | Website | www.tevapharm.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $54.93B | P/E | 14.53 | Forward P/E | 13.63 | PEG | -2.15 |
| P/S | 4.46 | P/B | 9.97 | P/CF | 40.74 | P/FCF | 57.37 |
| Sales | $17.31B | Sales 1Y | 4.13% | Sales 3Y | 15.3% | Sales 5Y | 6.07% |
| EPS | $2.93 | EPS 1Y | -475% | EPS 3Y | -129.74% | EPS 5Y | -116.81% |
| Sales QoQ | 4.04% | EPS QoQ | -258.06% | Sales QoQ Avg | 0.25% | EPS QoQ Avg | -54.37% |
| Gross Margin | 52.47% | Operating Margin | 11.45% | Profit Margin | 4.08% | ROCE | 8.19% |
| ROA | 2% | ROE | 9% | Altman Z Score | 0.95 | Piotroski Score | 7 |
| Current Ratio | 0.88 | Quick Ratio | 0.67 | Cash Ratio | 0.23 | Op. CF Ratio | 0.03 |
| Debt/Equity | 2.18 | Debt/Assets | 0.42 | Lt Debt/Equity | 1.6 | Lt Debt/Cap. | 0.61 |
| Intrst Cov. | 2.2 | Inventory Turnover | 2.56 | Asset Turnover | 0.43 | Receivables Turnover | 4.96 |
| Enterprise Value | $54.93B | P/E Ratio | 14.53 |
| Forward P/E | 13.63 | PEG Ratio | -2.15 |
| P/S Ratio | 4.46 | P/B Ratio | 9.97 |
| P/CF Ratio | 40.74 | P/FCF Ratio | 57.37 |
| EPS | $2.93 | EPS Growth 1Y | -475% |
| EPS Growth 3Y | -129.74% | EPS Growth 5Y | -116.81% |
| Revenue Growth 1Y | 4.13% | Gross Margin | 52.47% |
| Operating Margin | 11.45% | Profit Margin | 4.08% |
| ROE | 9% | ROA | 2% |
| ROCE | 8.19% | Current Ratio | 0.88 |
| Quick Ratio | 0.67 | Cash Ratio | 0.23 |
| Debt/Equity | 2.18 | Interest Coverage | 2.2 |
| Altman Z Score | 0.95 | Piotroski Score | 7 |
Teva Pharmaceutical Industries (TEVA) valuation & financials
Teva Pharmaceutical Industries (TEVA) has a market capitalization of $49.67B and trades at a price-to-earnings ratio of 14.5. It operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic).
Teva Pharmaceutical Industries's revenue grew +4.1% over the last year.
Teva Pharmaceutical Industries's next earnings report is scheduled for January 27, 2027 before market open (provider scheduled date); analysts estimate EPS of $0.70. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)